

Christoph Kamm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041154/publications.pdf>

Version: 2024-02-01

21
papers

864
citations

687220

13
h-index

752573

20
g-index

21
all docs

21
docs citations

21
times ranked

1478
citing authors

#	ARTICLE	IF	CITATIONS
1	Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. <i>Annals of Neurology</i> , 2016, 79, 646-658.	2.8	218
2	Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 317-325.	4.9	196
3	Autoimmune disorders affecting both the central and peripheral nervous system. <i>Autoimmunity Reviews</i> , 2012, 11, 196-202.	2.5	74
4	SUSCEPTIBILITY TO <i>DYT1</i> DYSTONIA IN EUROPEAN PATIENTS IS MODIFIED BY THE D216H POLYMORPHISM. <i>Neurology</i> , 2008, 70, 2261-2262.	1.5	73
5	Identification and functional analysis of novel THAP1 mutations. <i>European Journal of Human Genetics</i> , 2012, 20, 171-175.	1.4	48
6	Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. <i>Neurology</i> , 2017, 89, 1043-1049.	1.5	45
7	Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. <i>Neurology</i> , 2020, 94, e2109-e2120.	1.5	31
8	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1049-1063.	1.7	29
9	A novel heterozygous variant in <i>ERLIN2</i> causes autosomal dominant pure hereditary spastic paraplegia. <i>European Journal of Neurology</i> , 2018, 25, 943.	1.7	27
10	Validation of a self-completed Dystonia Non-Motor Symptoms Questionnaire. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2054-2065.	1.7	20
11	Novel <i>GNAL</i> mutations in two German patients with sporadic dystonia. <i>Movement Disorders</i> , 2014, 29, 1833-1834.	2.2	18
12	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.	1.8	15
13	Prominent White Matter Involvement in Multiple System Atrophy of Cerebellar Type. <i>Movement Disorders</i> , 2020, 35, 816-824.	2.2	15
14	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. <i>Frontiers in Neurology</i> , 2021, 12, 677551.	1.1	15
15	Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. <i>Frontiers in Neurology</i> , 2019, 10, 1098.	1.1	12
16	No evidence for <i>THAP1</i> / <i>DYT6</i> variants as disease modifiers in <i>DYT1</i> dystonia. <i>Movement Disorders</i> , 2011, 26, 2136-2137.	2.2	10
17	Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®). <i>Journal of the Neurological Sciences</i> , 2015, 350, 110-111.	0.3	7
18	Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 351-362.	1.7	5

#	ARTICLE	IF	CITATIONS
19	New clinical insights into combined central and peripheral demyelination (CCPD). Journal of the Neurological Sciences, 2016, 364, 27-28.	0.3	3
20	Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome. Frontiers in Neurology, 2018, 9, 381.	1.1	3
21	Neues zur Genetik von Dystonien: Mutationen in den Genen VPS16 und VPS41 als Ursache einer Dystonie mit Beeinträchtigung der Fusion lysosomaler Vesikel. DGNeurologie, 2021, 4, 56-57.	0.0	0